Liraglutide, Bariatric Surgery, and Lifestyle Compared for Weight Loss and NASH in Obese Asian Adults

Non-alcoholic fatty liver disease (NAFLD), particularly its severe form Non-alcoholic steatohepatitis (NASH), is a growing global health concern, especially in the Asia-Pacific region, where it's projected to affect 300 million obese individuals by 2030. NASH, characterized by hepatic steatosis, inflammation, and hepatocyte injury, can lead to irreversible liver damage. While weight loss is the primary treatment, sustained compliance with lifestyle modifications is challenging, and bariatric surgery, though effective, faces limitations in cost and patient acceptance. The efficacy of current pharmacological options for NASH remains unclear, highlighting a need for effective alternatives.